Author

G. Borges

Observed name: Giuliano Borges

Institutions: Instituto de Tecnologia do Paraná, Instituto de Oncologia do Paraná, Instituto de Pesquisas Cananéia

Observed institutions: Instituto de Tecnologia do Paraná, Instituto de Oncologia do Paraná, Instituto de Pesquisas Cananéia

ORCID: 0000-0002-0737-7922

Observed ORCID: 0000-0002-0737-7922

OpenAlex ID: A5143565017

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study

2025 · B. Pistilli, K. Jhaveri, et al. · Annals of Oncology · 32

Abstract RF7-01: Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study

2026 · H. Rugo, S. M. Tolaney, et al. · Clinical Cancer Research · 5

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

2026 · H.S. Rugo, K. Jhaveri, et al. · ESMO Open · 4

Elacestrant in Combination with Everolimus for Estrogen Receptor–Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

2026 · Hope S. Rugo, Sara M. Tolaney, et al. · Clinical Cancer Research · 2

Works count: 4

Citation count: 43

H-index: 3

I10-index: 1